DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Waldenström Macroglobulinemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Lymphoblastic Lymphoma

Interventions: Drug: cyclophosphamide
Drug: etoposide
Radiation: iodine I 131 tositumomab
Procedure: quality-of-life assessment
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-12-11

Last Posted Date: 2017-08-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 111

Registration Number: NCT00073918

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-12-11

Last Posted Date: 2015-02-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00073931

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders

First Posted Date: 2003-11-11

Last Posted Date: 2010-06-17

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00006367

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
University of Illinois College of Medicine, Chicago, Illinois, United States

and more 6 locations

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Phase 2

Completed

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Hepatosplenic T-cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Small Intestine Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Splenic Marginal Zone Lymphoma

Interventions: Drug: gemcitabine hydrochloride
Drug: carboplatin
Drug: dexamethasone
Biological: rituximab

First Posted Date: 2003-11-05

Last Posted Date: 2017-06-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00072514

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-10-07

Last Posted Date: 2010-08-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00003868

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Recurrent Non-Hodgkin Lymphoma
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Hodgkin Lymphoma
Recurrent Adult Acute Myeloid Leukemia

Interventions: Biological: Therapeutic Allogeneic Lymphocytes

First Posted Date: 2003-09-11

Last Posted Date: 2020-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00068718

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇩🇪
Universitaet Leipzig, Leipzig, Germany

and more 1 locations

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Chronic Myeloproliferative Disorders
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Leukemia
Precancerous/Nonmalignant Condition
Small Intestine Cancer
Myelodysplastic Syndromes

First Posted Date: 2003-08-28

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00005804

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Radiation: iodine I 131 monoclonal antibody BC8
Drug: busulfan
Drug: cyclophosphamide
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: cyclosporine
Drug: methotrexate
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2017-08-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00005940

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Pacific Northwest National Laboratory, Richland, Washington, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

Biological Therapy in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-07-08

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00045357

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-06-20

Last Posted Date: 2010-05-13

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00025545

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy